Fairfield, Bush & Co. Organon & Co. Transaction History

Fairfield, Bush & Co.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$10.95 - $17.32 $70,211 - $111,055	-6,412 Reduced 41.72%	8,956 $129 Million
Q3 2023 Nov 15, 2023	BUY	$16.59 - $23.77 $99 - $142	6 Added 0.04%	15,368 $267 Million
Q2 2023 Aug 15, 2023	BUY	$19.27 - $24.63 $115 - $147	6 Added 0.04%	15,362 $320 Million
Q1 2023 May 15, 2023	SELL	$21.42 - $32.08 $11,888 - $17,804	-555 Reduced 3.49%	15,356 $361 Million
Q4 2022 Feb 14, 2023	SELL	$23.31 - $28.61 $70,233 - $86,201	-3,013 Reduced 15.92%	15,911 $444 Million
Q3 2022 Nov 07, 2022	BUY	$23.4 - $34.25 $20,638 - $30,208	882 Added 4.89%	18,924 $443,000
Q2 2022 Aug 09, 2022	BUY	$31.66 - $38.9 $55,088 - $67,686	1,740 Added 10.67%	18,042 $609,000
Q1 2022 May 06, 2022	BUY	$30.45 - $39.36 $14,646 - $18,932	481 Added 3.04%	16,302 $569,000
Q4 2021 Feb 09, 2022	BUY	$28.67 - $37.13 $2,207 - $2,859	77 Added 0.49%	15,821 $482,000
Q3 2021 Nov 08, 2021	BUY	$28.63 - $35.64 $450,750 - $561,116	15,744 New	15,744 $516,000

791

193M

1.71M

865K

Ticker OGN
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 254,330,000
Market Cap $3.75B
Description
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

Stay updated on Fairfield, Bush & Co. with notifications on news.